Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges-Reference-Cited by-同舟云学术

Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges

Published:2024-05 Issue: Volume:154 Page:155835
ISSN:0026-0495
Container-title:Metabolism
language:en
Short-container-title:Metabolism

Author:

Kokkorakis Michail,Boutari Chrysoula,Hill Michael A.,Kotsis Vasilios,Loomba Rohit,Sanyal Arun J.,Mantzoros Christos S.

Publisher

Elsevier BV

Reference60 articles.

1. Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: a “non-invasive alternative” to liver biopsy?;Katsiki;Metabolism,2019

2. Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease;Polyzos;Metabolism,2014

3. Steatotic liver disease: pathophysiology and emerging pharmacotherapies;Kokkorakis;Pharmacol Rev,2024

4. From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need;Kokkorakis;Metabolism,2023

5. A multisociety Delphi consensus statement on new fatty liver disease nomenclature;Rinella;J Hepatol,2023

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regional gray matter changes in steatotic liver disease provide a neurobiological link to depression: A cross-sectional UK Biobank cohort study;Metabolism;2024-10

2. Management of patients with the cardio renal liver metabolic syndrome: The need for a multidisciplinary approach in research, education and practice;Metabolism;2024-10

3. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases;Metabolism;2024-10

4. Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research;Nutrients;2024-09-02

5. The lipopolysaccharide-TLR4 axis regulates hepatic glutaminase 1 expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis;Metabolism;2024-09